Pharvaris NV Aktie News

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Pharvaris stock surged Wednesday — and KalVista reversed higher — on promising test results for an HAE treatment.

Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours, significantly faster versus placebo (p

Increased Pharvaris stake by 500,000 shares, with a net position value change of $67.83 million Transaction represented 0.3% of General Atlantic, L.P.'s 13F reportable assets under management (AUM) Post-trade holding: 8,031,252 shares valued at $200.38 million The Pharvaris position now accounts for 6.0% of fund AUM, which places it outside the fund's top five holdings

I initiate Pharvaris with a buy rating and $40 target price, driven by its differentiated oral bradykinin B2 antagonist franchise for HAE. PHVS's late-stage pipeline targets both on-demand and prophylactic HAE treatment, with pivotal phase 3 data expected by year-end 2025. Deucrictibant's validated mechanism, strong phase 2 results, and regulatory precedent de-risk the upcoming phase 3 readout,...

Sold 122,106 shares of Pharvaris N.V, reducing position value by $21.23 million Post-trade holding: 3,181,275 shares valued at $79.37 million Position now accounts for 5.27% of AUM, ranking as the fund's 4th-largest holding

Topline data for RAPIDe-3, a pivotal Phase 3 study of deucrictibant immediate-release capsule for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment in CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release tablet for prophylaxis of HAE attacks, is progressing as planned; topline data anticipated in 2H2026 Initiated CREAATE, a pivotal Phase 3 study of deucrictib...

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the 20...